Credit Suisse’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-536,076
| Closed | -$18.5M | – | 4557 |
|
|
2020
Q3 | $18.5M | Buy |
536,076
+370,958
| +225% | +$7.9M | 0.01% | 1069 |
|
|
2020
Q2 | $2.76M | Buy |
165,118
+115,849
| +235% | +$1.97M | ﹤0.01% | 2131 |
|
|
2020
Q1 | $711K | Sell |
49,269
-6,603
| -12% | -$169K | ﹤0.01% | 2910 |
|
|
2019
Q4 | $1.87M | Buy |
55,872
+22,454
| +67% | +$628K | ﹤0.01% | 2648 |
|
|
2019
Q3 | $699K | Buy |
33,418
+2,385
| +8% | +$48.7K | ﹤0.01% | 3234 |
|
|
2019
Q2 | $646K | Sell |
31,033
-5,368
| -15% | -$111K | ﹤0.01% | 3246 |
|
|
2019
Q1 | $814K | Buy |
36,401
+2,686
| +8% | +$63.2K | ﹤0.01% | 3048 |
|
|
2018
Q4 | $807K | Buy |
33,715
+6,740
| +25% | +$174K | ﹤0.01% | 2950 |
|
|
2018
Q3 | $737K | Sell |
26,975
-16,185
| -38% | -$458K | ﹤0.01% | 3073 |
|
|
2018
Q2 | $1.16M | Sell |
43,160
-17,689
| -29% | -$541K | ﹤0.01% | 2903 |
|
|
2018
Q1 | $1.94M | Buy |
60,849
+26,830
| +79% | +$944K | ﹤0.01% | 2453 |
|
|
2017
Q4 | $1.29M | Sell |
34,019
-6,690
| -16% | -$216K | ﹤0.01% | 2798 |
|
|
2017
Q3 | $1.01M | Buy |
40,709
+9,315
| +30% | +$201K | ﹤0.01% | 3089 |
|
|
2017
Q2 | $645K | Sell |
31,394
-11,051
| -26% | -$211K | ﹤0.01% | 2972 |
|
|
2017
Q1 | $924K | Buy |
42,445
+5,248
| +14% | +$108K | ﹤0.01% | 2921 |
|
|
2016
Q4 | $760K | Buy |
37,197
+15,231
| +69% | +$311K | ﹤0.01% | 3221 |
|
|
2016
Q3 | $329K | Buy |
21,966
+6,487
| +42% | +$87.6K | ﹤0.01% | 3625 |
|
|
2016
Q2 | $167K | Sell |
15,479
-3,296
| -18% | -$44.8K | ﹤0.01% | 3934 |
|
|
2016
Q1 | $255K | Buy |
+18,775
| New | +$293K | ﹤0.01% | 3587 |
|
|
2015
Q4 | – | Sell |
-65,924
| Closed | -$1.67M | – | 4423 |
|
|
2015
Q3 | $1.67M | Buy |
+65,924
| New | +$1.54M | ﹤0.01% | 2388 |
|
Credit Suisse's AIMT Position: Q4 2020 in Review
Credit Suisse sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 536,076 shares — an estimated $18.5M sold.
Credit Suisse first reported a position in AIMT in Q3 2015 and held it in 20 quarters. The position peaked at $18.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Credit Suisse reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Credit Suisse sold 536,076 Aimmune Therapeutics shares in Q4 2020, an estimated $18.5M.
- Credit Suisse first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 20 quarters.
- Credit Suisse's Aimmune Therapeutics position peaked at $18.5M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Credit Suisse's 13F filing for Q4 2020, filed 12 Feb 2021.